RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 22, 2007, titled "Terapia Ranbaxy receives EU compliance for manufacturing and import authorization". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_220207.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 13, 2007, titled "Ranbaxy products listed on AOK, Germany's largest Health Insurance". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_13022006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated February 12, 2007, titled "Ranbaxy Launches Atorvastatin In Denmark." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_press_130207.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated February 08, 2007, titled "Ranbaxy Gains Final US FDA approval for Sertraline Hydrochloride Tablets." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_08022007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 07, 2007, titled "Ranbaxy announces global entry into Biosimilars with Zenotech - Targets EU markets first". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR__070207.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated February 06, 2007, titled "Ranbaxy Signs a New R&D Agreement with GSK." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_06022007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 30,2007, titled "Ranbaxy gains FDA approval to market Amoxicillin and Clavulanate Potassium for Oral Suspension USP". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_31012007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 29,2007, titled "Ranbaxy launches two NDDS Urology products in India - Niftran developed in-house; Eligard in-licensed from US drug company". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pressrelease_290107.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 26, 2007, titled "Canadian Federal Court Grants Favorable Decision to Ranbaxy on Pfizer's Atorvastatin Patent". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_270107.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 18, 2007, titled "Ranbaxy records Robust Growth for Q4 2006, Net Profit up 167% at Rs 1,859 MN. Global Sales at Rs 17,077 MN, + 22% Growth - Annual Sales touch Rs 60,698 MN, + 17%, Net Profit up 97% at Rs 5,204 MN". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_180107.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 02, 2007, titled "Ranbaxy Granted Final USFDA Approval to Manufacture and Market Atenolol Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_020120076.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated December 21, 2006, titled "Ranbaxy Granted Final USFDA Approval To Market Simvastatin 5, 10, 20 And 40 MG Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Press2_211206.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated December 20, 2006, titled "Australian Federal Court Grants Favorable Decision to Ranbaxy on Pfizer's Atorvastatin Patent." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_press_211206.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated December 18, 2006, titled "Ranbaxy and DST, Govt. of India, join hands in the area of New Drug Discovery Research." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_18122006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 14, 2006, titled "Ranbaxy granted final USFDA approval to manufacture and market CEFPROZIL Anti-Infective Tablets". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_141206.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, December 11, 2006, titled "Ranbaxy Appoints Atul Sobti as COO". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_11122006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 1, 2006 titled "Ranbaxy acquires Be-Tabs Pharmaceuticals, the 5th largest generics company in South Africa for USD 70 MN". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR2_01122006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 30,2006, titled "Ranbaxy organizes WALKATHON' 06 in Mumbai, India, on World Aids Day - For the first time in India, Doctors to come together to express solidarity; Ranbaxy also introduces Paediatric ARV combination medicines in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_0112006.zip target=NEW> For more de

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated November 15, 2006, titled "Ranbaxy granted favorable decision by the U.S. Court of Appeals regarding Marketing Exclusivity for SIMVASTATIN 80 mg-Decision has wide-ranging implications for Ranbaxy as well as other generic pharmaceutical manufacturers". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_15112006.zip target=NEW> Fo

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated November 03, 2006, titled "Ranbaxy Receives Tentative USFDA Approval to Manufacture and Market Cetirizine Hydrochloride Syrup". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_03112006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated October 23, 2006, titled "Ranbaxy signs licensing agreement with Swiss Company Debiopharm, for NCE Drug in the Gastroenterology Segment - Marketing rights in India, Bangladesh and Nepal". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_231006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated October 19, 2006, titled "Ranbaxy Q3 PAT Up 651% at Rs.1,404 MN as Global Sales Scale Rs.16,404 MN, Up 26%." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19102006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 06, 2006, titled "Ranbaxy Signs Licensing and Supply Agreement to Market a Second Licensed Generic in Canada". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_06102006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 27, 2006, titled "Ranbaxy launches 'Storvas', the first generics version of Atorvastatin in Malaysia - earlier introduced the first generic alternative of Oseltamivir". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_270906.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 22,2006, titled "Ranbaxy in pact with Gilead Sciences anti-HIV drug Tenofovir". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_250906.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 21, 2006, titled "Ranbaxy receives approval to commercialize Furosemide Tablets in the US". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_210906.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 18, 2006, titled "Ranbaxy in-licenses NDDS cardiovascular drug from Ethypharm for Indian market", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated September 13, 2006, titled "Ranbaxy Invalidates Pfizers 281 Patent in the Netherlands". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated September 12, 2006, titled "Ranbaxy Launches Avessa for the treatment of Asthma - World's First Novel Product Introduced in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 11,2006, titled "Ranbaxy receives USFDA approval to market Loperamide Hydrochloride and Simethicone Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 30,2006, titled "Ranbaxy wins on two additional Atorvastatin Patents in Norway - Three of four patent rulings now favour Ranbaxy". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 18, 2006, titled "Ranbaxy Launches Soliten for Treatment of Urology Disorder Product Introduced for the First Time in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 04,2006, titled "Ranbaxy receives tentative approval from US FDA to market Risperidone Oral Solution". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 03,2006, titled "Ranbaxy Invalidates Pfizer's '995 Lipitor U.S. Patent - CAFC overturns earlier District Court ruling on the same patent". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 02,2006, titled "Ranbaxy's US subsidiary Ohm Labs receives Prestigious Private Label Supplier of the Year award from AmerisourceBergen". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated July 20, 2006, titled "Ranbaxy Q2 Global Sales at Rs. 14,464 MN, Records 7% Growth - Net Profit At Rs. 1,211 MN, Record 20% Growth- Ebidta Margins at 18.3% Records Growth of 56%". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 19, 2006, titled "Ranbaxy signs licensing and supply agreement for the Canadian market First Indian Company to market a licensed generic in Canada". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 18, 2006, titled "Ranbaxy to acquire the Mundogen Generic Business of Glaxosmithkline in Spain". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboraetories Ltd has informed the Exchange regarding a press release dated July 17,2006, titled "Ranbaxy's Joint Venture in Japan launches Generic Clarithromycin & Terbinafine Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated June 30, 2006, titled "Ranbaxy Receives US FDA Approval to Market Cefprozil Suspension". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 28,2006, titled "U.K. Appeals Court Affirms Mixed High Court of Justice's Ruling in Lipitor� Case". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 23, 2006, titled "Ranbaxy Receives USFDA Approval To Market 80MG Simvastatin Tablets with 180-Day Exclusivity - Cholesterol - Lowering Simvastatin Currently Marketed in the U.S. as Zocor �". The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, June 09, 2006, titled "Ranbaxy to Market Zonisamide Capsules in the US" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 08, 2006, titled "Ranbaxy achieves closure on Terapia deal as Romanian Competition Council approves acquisition". The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, June 07, 2006, titled "Ranbaxy Inc. Announces a Strategic Partnership with Zenotech for Oncology Products". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, June 02, 2006, titled "Ranbaxy receives approval from US FDA to market Doxycycline Tablets" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, May 24, 2006, titled, "Ranbaxy in-licences NDDS analgesic molecule from Ethypharm-France, for India - Adds muscle to its strategic portfolio of Novel drugs".The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a Press Release dated May 24,2006, titled "Ranbaxy gains WHO pre-qualification for four more ARVs". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, May 17, 2006, titled "Ranbaxy in-licences new Asthma drug from European Laboratories, Netherlands - Product to be marketed in India for the first time". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, April 25, 2006, titled, "Ranbaxy Sucessfully Invalidates Atorvastatin Patent in Austria". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)